Healthy Living/WellnessFDA requests investigation of cholesterol drug's neurocognitive risks The FDA has asked that Sanofi and Regeneron test a new cholesterol-fighting drug, alirocumab, for the possibility of neurocognitive inference or damage.by Tabitha Laffernis
Healthy Living/WellnessTestosterone replacement drug Aveed gets the FDA's stamp of approvalby Tabitha Laffernis
Healthy Living/WellnessFDA allows Plan B generic morning-after pills to be sold OTC without age restrictionsby Rhodilee Jean Dolor
Healthy Living/WellnessWhy FDA-approved Zohydro painkiller may be a bad idea after allby Maryanne Moll
Healthy Living/WellnessTestosterone drug should carry warning of heart risk, consumer group saysby Pierre Dumont
Healthy Living/WellnessProposal for revamped nutrition labels unveiled by the FDA and Michelle Obamaby Tabitha Laffernis
Healthy Living/WellnessFDA mulls giving green light to controversial 3-person embryo fertilization techniqueby Alex Saltarin
Healthy Living/Wellness3-person embryo technique, mitochondrial replacement, scrutinized by the FDAby Tabitha Laffernis
Healthy Living/WellnessE-cigarette lobbyists face uphill battle against FDA regulationsby Maryanne Moll
South Korea's ICT Exports Hit All-Time Growth Rate of 125.9% in April, Driven by AI Server Chip Demand